Winners of the CSL Behring – Prof. Heimburger Award 2010 announced

MARBURG, Germany, March 29, 2010. CSL Behring, a global leader in plasma biotherapeutics, announced today the five grant winners of the “CSL Behring – Prof. Heimburger Award 2010”. Each award carries a stipend of €20,000 (US $26,920) to support physicians with their preclinical and/or clinical research in hemophilia and coagulation. The recipients were honoured at a symposium in Marburg to recognize their achievements and research grant proposals.

Established by CSL Behring in 2008, the Award is named in honor of Prof. Norbert Heimburger, one of the pioneers of modern-day coagulation therapy. He was a long-term employee of CSL Behring and was instrumental in developing the first virus-safe plasma products by the utilization of pasteurization.

“We are very proud to recognize and celebrate the next generation of aspiring, young investigators who will establish their own independent research project and who demonstrate Prof. Heimburger’s passion for advancing the understanding and science of coagulation disorders,” said Marcus Stockschaeder, MD, Director of Medical Affairs Coagulation at CSL Behring.
The CSL Behring – Prof. Heimburger Award 2010 recipients and their projects are as follows:

- **Margareth Castro Ozelo**, Hemoentro UNICAMP, State University of Campinas, Campinas, Sao Paola, Brazil
  
  o *Characterization of genetic risk factors for inhibitor development in a Brazilian severe haemophilia A population*

- **Liesbeth De Waele**, Department of Pediatrics, University Hospital Gasthuisberg, Leuven, Belgium
  
  o *Gene therapy for severe macro-thrombocytopenia caused by GATA1 deficiency*

- **Antonio Follenzi**, Department of Histology, University of Piemonte Orientale, Medical School, Novara, Italy
  
  o *iPS-based strategy to correct the bleeding phenotype in hemophilia A*

- **Christophe Goubau**, Centre for Molecular and Vascular Biology and Department of Pediatrics, University Hospital Leuven, Ottignies, Belgium
  
  o *Identification of novel molecular players in (neuro) storage pool disease*

- **Attie Tuinenburg**, Van Creveldkliniek/Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
  
  o *Coronary artery calcification measured with multi detector-row computed tomography in patients with hemophilia A.*

The applications were reviewed by a committee of four eminent clinicians in the coagulation field:

**Thomas Abshire, MD**

Medical Services and the Medical Sciences Institute,

BloodCenter of Wisconsin, Milwaukee, USA
David Lillicrap, MD
Department of Pathology and Molecular Medicine,
Queen’s University, Kingston, Ontario, Canada

Claude Négrier, MD
Regional Centre for the Treatment of Haemophilia,
Hopital Edouard Herriot, Lyon, France

Johannes Oldenburg, MD
Institute of Experimental Haematology and Transfusion Medicine,
Universitätsklinikum Bonn, Bonn, Germany

Last year’s winners also updated their research program progress. These included Francesco Dentali, Department of Clinical Medicine, University of Insubria, Varese, Italy; Luis Graça, Faculty of Medicine, University of Lisbon, Portugal; Albert Mairuhu, Beth Israel Deaconess Medical Center, Boston, USA; Grazia Loredana Mendolicchio, Thrombosis Center, Humanitas Clinical Institute, Rozzano, Italy, and Rochelle Winikoff, Division of Hematology-Oncology, University Hospital Center Sainte-Justine, Montréal, Canada;

Applications for the 2011 award close October 8, 2010. More information regarding the “CSL Behring – Prof. Heimburger Award” and specific criteria for 2011 applications can be found at: www.cslbehring.com/ProfHeimburgerAward.

About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a
range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.CSLBehring.com.

Contact

Sheila A. Burke, Director, Communications & Public Relations
Worldwide Commercial Operations
CSL Behring
+1-610-878-4209
Sheila.Burke@cslbehring.com